FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  Katkin Keith						2. Issuer Name <b>and</b> Ticker or Trading Symbol Syndax Pharmaceuticals Inc [ SNDX ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Natkiii Neitii													X Directo	or		10% Ov	ner	
(Last)	Last) (First) (Middle) C/O SYNDAX PHARMACEUTICALS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 03/29/2017								Officer below)	(give title		Other (s below)	pecify	
35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WALTH	Street) WALTHAM MA 02451		02451		X Forn									filed by One Reporting Person filed by More than One Reporting on				
(City)	(S	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution Date			, Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 a		Benefici	es ally Following	Form ly (D) or		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3	tion(s)			inisti. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code (				6. Date Exercisable Expiration Date (Month/Day/Year)		:	7. Title and Ame of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$13.78	03/29/2017		A		25,000		(1)	C	03/29/2027	Common Stock	25,000	\$0.00	25,000		D		

## **Explanation of Responses:**

1. 1/36th of the shares subject to the option shall vest monthly over a three-year period.

## Remarks:

/s/ Michael A. Metzger, as 03/31/2017 Attorney-in-Fact

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.